Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
British Journal of Clinical Pharmacology|March 17, 2020
Chimeric antigen receptor T-cell therapies: Optimising the doseNathaniel Dasyam, Philip George, Robert Weinkove
Critical Reviews in Oncogenesis|February 29, 2024
Recruiting Natural Killer T Cells to Improve Vaccination: Lessons from Preclinical and Clinical StudiesOlivia K Burn, Nathaniel Dasyam, Ian F Hermans
Clinical & Translational Immunology|May 22, 2019
Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerationsRobert Weinkove, Philip George, Nathaniel Dasyam, et al.
Journal of Natural Products|May 27, 2014
Identification and bioactivity of 3-epi-xestoaminol C isolated from the New Zealand brown alga Xiphophora chondrophyllaNathaniel Dasyam, Andrew B Munkacsi, Nazmi H Fadzilah, et al.
Frontiers in Immunology|November 5, 2021
Mucosal-Associated Invariant T (MAIT) Cell Dysfunction and PD-1 Expression in Prostate Cancer: Implications for ImmunotherapyEllie-May Jarvis, Shaun Collings, Astrid Authier-Hall, et al.
Bioorganic & Medicinal Chemistry Letters|April 18, 2015
Synthesis of mycothiol conjugate analogues and evaluation of their antimycobacterial activityScott W Riordan, Jessica J Field, Hilary M Corkran, et al.
Scientific Reports|July 2, 2025
Jurkat T-cell lines exhibit marked genomic instability affecting karyotype, mutational profile, gene expression, immunophenotype and functionAndrew Wilson, Nathaniel Dasyam, Felix O'Hagan, et al.
BMJ Open|February 12, 2020
Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)Philip George, Nathaniel Dasyam, Giulia Giunti, et al.
Oncoimmunology|June 17, 2022
Intratumoural administration of an NKT cell agonist with CpG promotes NKT cell infiltration associated with an enhanced antitumour response and abscopal effectKef K Prasit, Laura Ferrer-Font, Olivia K Burn, et al.
Cancer Immunology, Immunotherapy : CII|March 7, 2023
A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanomaNathaniel Dasyam, Katrina J Sharples, Catherine Barrow, et al.
Pageof 1